I couldn't agree more. The example I always throw out is that if I have one admission for diabetic ketoacidosis that ends up in the intensive care unit, I could probably pay for that patient's lifetime of insulin for the cost of that one visit. That doesn't even take into account the people with poorly controlled diabetes who have heart attacks after 20 years, end up on dialysis, require amputations, and these sorts of things. It's nice that we're starting to get some data to prove these assumptions that clinical practitioners have always had.
This is a bit of an open question. Where would you say the provinces are getting their best possible evidence to make decisions on pharmacare? What will we need to make sure we have the best evidence? How do we collect all this evidence beyond what you're describing here? What kind of national surveillance of outcomes and cost effectiveness would we need?